Medical Degree: Albert Einstein College of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowships: University of California, Los Angeles
Jesse Goodman, M.D., M.P.H., is a Professor of Medicine and directs Georgetown’s Center on Medical Product Access, Safety and Stewardship (COMPASS) which focuses on informing science based policy to address public health needs, including emerging infections and antimicrobial resistance, and, from 2020-2023, hosting COVAT, the Covid Vaccine Analysis Team, a multi-institutional expert group providing objective information on COVID vaccines.
He is an Attending Physician in Infectious Diseases at Georgetown University, Washington DC Veteran’s Administration and Walter Reed National Military Medical Centers.. He previously was Chief Scientist and Deputy Commissioner for Medicine and Public Health of the U.S. Food and Drug Administration (FDA), serving in the US government’s senior leadership for major public health responses, including the 2009 H1N1 pandemic and the White House 2010 Medical Countermeasures Review. Prior to being Chief Scientist, he directed FDA’s Center for Biologics Evaluation and Research (CBER) and before that served as Senior Advisor to the FDA Commissioner, co-chairing the first U.S. Task Force to Combat Antimicrobial Resistance. Prior to his government service, he was Professor and Chief of Infectious Diseases at the University of Minnesota, where his laboratory isolated and characterized Anaplasma phagocytophilum, the causative agent of the tick-borne disease human granulocytic anaplasmosis, and used molecular tools to characterize B. burgdorferi infections of humans, and where he conducted studies on treatment and prevention of infections in immunocompromised hosts.
He has served on a variety of CDC, NIH, DOD, CEPI and WHO Advisory Committees, He is past president of the US Pharmacopeia (USP), a voluntary standards organization devoted to global medicines quality. He serves as an independent scientific advisor on the boards of USP, GSK, Intellia Therapeutics (developing CRISPR based medicines) and BiomX (developing bacteriophage treatments for infectious diseases). He trained in Infectious Diseases and Hematology/Oncology at UCLA and has been elected to the American Society for Clinical Investigation and the National Academy of Medicine.
When not in the midst of ID and public health, he likely can be found rout for a run or with his grandkids or honeybees.
Selected Publications
Venne DM et al. Review and analysis of the overlapping threats of carbapenem and polymyxin resistant E. coli and Klebsiella in Africa. Antimicrob Resist Infect Control. 2023 Apr 4;12(1):29.
Baylor NW, Goodman JL. Vaccine Preparedness for the Next Influenza Pandemic: A Regulatory Perspective. Vaccines (Basel). 2022 Dec 13;10(12):2136
Goodman JL, Grabenstein JD, Braun MM. Answering Key Questions About COVID-19 Vaccines. JAMA. 2020. doi:10.1001/jama.2020.20590
Goodman JL, Borio L. Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis JAMA. 2020;10.1001/jama.2020.6434.
Goodman JL. Studying “Secret Serums” — Toward Safe, Effective Ebola Treatments. NEJM August 20, 2014 DOI: 10.1056/NEJMp1409817
Herron, M.J., et al, Intracellular Parasitism by the Human Granulocytic Ehrlichiosis Agent Through the P-selectin Ligand, PSGL-1. Science Jun 2 2000: 1653-1656.
Goodman JL. Ehrlichiosis--ticks, dogs, and doxycycline. NEJM. 341(3):195-7, 1999
Goodman, J.L., et al, Direct Cultivation of The Causative Agent From Patients with Human Granulocytic Ehrlichiosis. NEJM 334:209-215, 1996.
Goodman, J.L. et al, Bloodstream Invasion In Early Lyme Disease: Results From a Prospective, Controlled, Blinded Study Using the Polymerase Chain Reaction. Amer Jour Med 99:6-12, 1995.
Bradley, J.F., Johnson, R.C., and Goodman, J.L. The Persistence of Spirochetal Nucleic Acids in Active Lyme Arthritis. Annals of Internal Medicine 120:487-489, 1994.
Goodman, J.L., et al., A Controlled Trial of Fluconazole to Prevent Fungal infections in Patients Undergoing Bone Marrow Transplantation, NEJM 326:845-852, 1992.